JPS6042336A - 免疫グロブリンの製造方法 - Google Patents
免疫グロブリンの製造方法Info
- Publication number
- JPS6042336A JPS6042336A JP14968883A JP14968883A JPS6042336A JP S6042336 A JPS6042336 A JP S6042336A JP 14968883 A JP14968883 A JP 14968883A JP 14968883 A JP14968883 A JP 14968883A JP S6042336 A JPS6042336 A JP S6042336A
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- solution
- concentration
- peg
- purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 63
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 63
- 238000004519 manufacturing process Methods 0.000 title claims 5
- 239000002244 precipitate Substances 0.000 claims abstract description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 229960002449 glycine Drugs 0.000 claims abstract description 6
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 238000005349 anion exchange Methods 0.000 claims abstract 3
- 239000003480 eluent Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 24
- 230000002391 anti-complement effect Effects 0.000 claims description 22
- 108010008730 anticomplement Proteins 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 44
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 abstract description 7
- 238000010253 intravenous injection Methods 0.000 abstract description 5
- 239000006228 supernatant Substances 0.000 abstract description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- 230000003171 anti-complementary effect Effects 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 238000005341 cation exchange Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 238000000034 method Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- WEQHQGJDZLDFID-UHFFFAOYSA-J thorium(iv) chloride Chemical compound Cl[Th](Cl)(Cl)Cl WEQHQGJDZLDFID-UHFFFAOYSA-J 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14968883A JPS6042336A (ja) | 1983-08-18 | 1983-08-18 | 免疫グロブリンの製造方法 |
| DE19843430320 DE3430320A1 (de) | 1983-08-18 | 1984-08-17 | Verfahren zur herstellung von immunglobulin-praeparaten mit verminderter komplementaktivitaet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14968883A JPS6042336A (ja) | 1983-08-18 | 1983-08-18 | 免疫グロブリンの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6042336A true JPS6042336A (ja) | 1985-03-06 |
| JPH0582367B2 JPH0582367B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-11-18 |
Family
ID=15480636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14968883A Granted JPS6042336A (ja) | 1983-08-18 | 1983-08-18 | 免疫グロブリンの製造方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS6042336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
| DE (1) | DE3430320A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0278635A (ja) * | 1988-07-27 | 1990-03-19 | Biotest Ag | ＩｇＭを含有する静脈内投与のポリクローナル免疫グロブリン調製物の調製方法 |
| JP2003528803A (ja) * | 1999-05-20 | 2003-09-30 | アルファ・セラピューティック・コーポレーション | 静注用免疫グロブリンの２回ウイルス不活化方法 |
| WO2003088999A1 (fr) * | 2002-04-22 | 2003-10-30 | Mitsubishi Pharma Corporation | Procede de production d'une preparation d'immunoglobuline |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3641115A1 (de) * | 1986-12-02 | 1988-06-16 | Lentia Gmbh | Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins |
| US5525519A (en) * | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| DK2270044T3 (en) | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| TWI320788B (en) * | 2005-05-25 | 2010-02-21 | Hoffmann La Roche | Method for the purification of antibodies |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| JP6726666B2 (ja) | 2014-12-03 | 2020-07-22 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 免疫グロブリンを含む安定性が高められた医薬製品 |
-
1983
- 1983-08-18 JP JP14968883A patent/JPS6042336A/ja active Granted
-
1984
- 1984-08-17 DE DE19843430320 patent/DE3430320A1/de not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0278635A (ja) * | 1988-07-27 | 1990-03-19 | Biotest Ag | ＩｇＭを含有する静脈内投与のポリクローナル免疫グロブリン調製物の調製方法 |
| JP2003528803A (ja) * | 1999-05-20 | 2003-09-30 | アルファ・セラピューティック・コーポレーション | 静注用免疫グロブリンの２回ウイルス不活化方法 |
| WO2003088999A1 (fr) * | 2002-04-22 | 2003-10-30 | Mitsubishi Pharma Corporation | Procede de production d'une preparation d'immunoglobuline |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0582367B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-11-18 |
| DE3430320A1 (de) | 1985-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2266914C2 (ru) | Способ получения igg | |
| EP0447585B2 (de) | Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates | |
| JP3148222B2 (ja) | 非変性静脈内投与可能なＩｇＭ―及び／又は／ＩｇＡ―含有免疫グロブリン製剤及びその製造方法 | |
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| AU2001273907A1 (en) | A method of producing IgG | |
| JP2644946B2 (ja) | ＩｇＧ− モノクロナール抗体の精製方法及びその使用方法 | |
| US4022758A (en) | Isolation of coagulation factors I and VIII from biological material | |
| JPH07103044B2 (ja) | Ｃ１不活性化剤を含有する医薬の調製方法 | |
| JPH0393730A (ja) | 減感作剤 | |
| US3916026A (en) | Method for the preparation of gamma-globulin suitable for intravenous use | |
| JPS6042336A (ja) | 免疫グロブリンの製造方法 | |
| NL7907791A (nl) | Werkwijze voor het zuiveren van interferon. | |
| US4137307A (en) | Process for preparing haptoglobin aqueous solution using strong anion exchanger | |
| CN115768789A (zh) | 用于获得包含人血浆来源的免疫球蛋白m的组合物的方法 | |
| US2662046A (en) | Parenteral amino acid solution | |
| US4845078A (en) | Method for treating hematopoietic diseases | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| US4061735A (en) | Haptoglobin in aqueous solution and process for preparing the same | |
| JPS6160817B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CA1072444A (en) | Method of recovering immunoglobulin | |
| CA1105383A (en) | Immunoglobulin having a reduced complement fixation, a process for its preparation and agents containing this immunoglobulin | |
| JP2521551B2 (ja) | 抗血友病因子の製造方法 | |
| JPH0611705B2 (ja) | 血小板減少症治療剤 | |
| EP0116571B1 (en) | Method for making gamma globulin-containing compositions | |
| CN114249812A (zh) | 一种降低vWF制品中IgM含量的方法 |